Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 8/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24671788 | 0.95 | NPC1 (0.36) | GNAI3GNAO1GNAI1NPC1CACNA1G | |
| SCHEMBL23484948 | 0.83 | NPC1 (0.36) | GNAI3GNAO1GNAI1NPC1RAB9A | |
| SCHEMBL25851958 | 0.83 | ALDH1A1 (0.36) | GNAI3GNAO1GNAI1NPC1EPHX2 | |
| SCHEMBL23594109 | 0.82 | ALDH1A1 (0.36) | GNAI3GNAO1GNAI1NPC1ALDH1A1 | |
| SCHEMBL8283986 | 0.82 | NPC1 (0.42) | GNAI3GNAO1GNAI1NPC1CACNA1G | |
| SCHEMBL26804302 | 0.82 | ALDH1A1 (0.40) | GNAI3GNAO1GNAI1NPC1EPHX2 | |
| SCHEMBL22875054 | 0.80 | NPC1 (0.42) | GNAI3GNAO1GNAI1NPC1RAB9A | |
| SCHEMBL25030012 | 0.79 | NPC1 (0.39) | GNAI3GNAO1GNAI1NPC1RAB9A | |
| SCHEMBL26221592 | 0.79 | NPC1 (0.39) | GNAI3GNAO1GNAI1NPC1EPHX2 | |
| SCHEMBL26707720 | 0.78 | CACNA1G (0.41) | CACNA1GALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | GNAI3 2261/4885GNAO1 3201/4885GNAI1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.